Sie sind hier: UHH > Chemie > Institute und Abteilungen > Biochemie und Molekularbiologie > Publikationen > Carl-Wilhelm Vogel
Inhalt:
Kurzbiographie
| 1951 | geboren in Hamburg |
| 1976 | Promotion (Medizin) bei Eberhard Königk in Hamburg (Bernhard-Nocht-Institut) |
| 1976-1978 | Medizinalassistent (Universität Hamburg, Universität Kiel, Kreiskrankenhaus Geesthacht) |
| 1979-1982 | PostDoc an der Scripps Clinic and Research Foundation in La Jolla |
| 1982-1991 | Assistant/Associate/Full Professor Depts. of Biochemistry/Molecular Biology, Internal Medicine, and Lombardi Cancer Center, Georgetown University Washington |
| 1985 | Research Career Development Award, National Cancer Institute, USA |
| 1986 | Promotion (Biochemie) bei Günther Gercken in Hamburg |
| 1987 | Alan Berman Research Award Naval Research Laboratory Dept. of the Navy USA |
| 1990-1999 | Professor (C4) für Biochemie in Hamburg |
| 1991 | Member of the American Society for Clinical Investigation |
| 1995 | Kind-Philipp-Preis für Leukämie-Forschung |
| 1997 | Fellow of the American Society for Clinical Pathology |
| 1997 | Life Fellow College of American Pathologists |
| 1999- | Professor, Cancer Research Center of Hawaii at the University of Hawaii |
| 1999-2008 | Director of the Cancer Research Center of Hawaii at the University of Hawaii |
Weitere Informationen
Publikationen
(nur bis zum Ende Hamburger Zeit, bis 1999)1999 | |
| 1 |
Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys Jorn E. Schmitz; Michelle A. Lifton; Keith A. Reimann; David C. Montefiori; Ling Shen; Paul Racz; Klara Tenner-Racz; Markus W. Ollert; Meryl A. Forman; Rebecca S. Gelman; Carl-Wilhelm Vogel; Norman L. Letvin AIDS Research and Human Retroviruses 15, 195-202 (1999) |
| 2 |
A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody Jorn E. Schmitz; Meredith A. Simon; Marcelo J. Kuroda; Michelle A. Lifton; Markus W. Ollert; Carl-Wilhelm Vogel; Paul Racz; Klara Tenner-Racz; Bernard J. Scallon; Margaret Dalesandro; John Ghrayeb; E. Peter Rieber; Vito G. Sasseville; Keith A. Reimann American Journal of Pathology 154, 1923-1932 (1999) |
| 3 |
Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen Kerstin A. David; Markus W. Ollert; Caren Vollmert; Sven Heiligtag; Britta Eickhoff; Rudolf Erttmann; Reinhard Bredehorst; Carl-Wilhelm Vogel Cancer Research 59, 3768-3775 (1999) |
| 4 |
Natural human IgM-antibodies in neuroblastoma therapy: preliminary findings of a phase I/II clinical trial Caroline Schmitt; Kerstin A. David; J. Hiller; J. Schrum; Reinhard Bredehorst; Carl-Wilhelm Vogel; C. Löliger; Rudolf Erttmann Klinische Pädiatrie 211, 314-318 (1999) |
| 5 |
Serotype distribution and secretory acid proteinase activity of Candida albicans isolated from the oral mucosa of patients with denture stomatitis C. G. McMullan-Vogel; H. D. Jude; Markus W. Ollert; Carl-Wilhelm Vogel Oral Microbiology and Immunology 14, 183-189 (1999) |
| 6 |
Novel cobra venom factors and their use in lowering complement activity via recombinant proCVF Carl-Wilhelm Vogel; Reinhard Bredehorst; David C. Fritzinger; Michael A. Kock Patent: US 5922320 (A) 1999-07-13 |
| 7 |
In vivo binding pair pretargeting with antibodies and methotrexate analogs Nicholas Pomato; Richard P. McCabe; Gregory A. Hawkins; Reinhard Bredehorst; Chong-Ho Kim; Carl-Wilhelm Vogel Patent: US 5965106 (A) 1999-10-12 |
1998 | |
| 8 |
Protease-derivatized cobra venom factor with retention of bioactivity Markus W. Ollert; Patrick Ziegelmüller; Thomas Grunwald; Reinhard Bredehorst; Carl-Wilhelm Vogel Patent: US 5714344 (A) 1998-02-03 |
1997 | |
| 9 |
Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid Kerstin A. David; A. Ehrhardt; Markus W. Ollert; Rudolf Erttmann; Reinhard Bredehorst; Carl-Wilhelm Vogel European Journal of Cancer 33, 1937-1941 (1997) |
| 10 |
Mechanisms of in vivo antineuroblastoma activity of human natural IgM Markus W. Ollert; Kerstin A. David; C. Vollmert; Hartmut Juhl; Rudolf Erttmann; Reinhard Bredehorst; Carl-Wilhelm Vogel European Journal of Cancer 33, 1942-1948 (1997) |
| 11 |
Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells Hartmut Juhl; Eugene C. Petrella; Nai-Kong V. Cheung; Reinhard Bredehorst; Carl-Wilhelm Vogel Immunobiology 197, 444-459 (1997) |
| 12 |
Immunoconjugates Carl-Wilhelm Vogel; Reinhard Bredehorst -/- Herausgeber: R. Dulbecco Encyclopedia of Human Biology, 2nd Edition 4, 112.1-112.15 (1997), Verlag: Academic Press, San Diego |
1996 | |
| 13 |
Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans Kerstin A. David; Markus W. Ollert; Hartmut Juhl; Caren Vollmert; Rudolf Erttmann; Carl-Wilhelm Vogel; Reinhard Bredehorst Nature Medicine 2, 686-689 (1996) |
| 14 |
Naturally occurring humoral cytotoxicity against neuroblastoma (NB) cells in healthy persons and NB patients Rudolf Erttmann; Caroline Schmitt; Markus W. Ollert; Kerstin A. David; Reinhard Bredehorst; Carl-Wilhelm Vogel Pediatric Hematology and Oncology 13, 545-548 (1996) |
| 15 |
Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells Markus W. Ollert; Kerstin A. David; Caroline Schmitt; Alexander Hauenschild; Reinhard Bredehorst; Rudolf Erttmann; Carl-Wilhelm Vogel Proceedings of the National Academy of Sciences of the United States of America 93, 4498-4503 (1996) |
| 16 |
Structure and function of cobra venom factor, the complement-activating protein in cobra venom Carl-Wilhelm Vogel; Reinhard Bredehorst; David C. Fritzinger; Thomas Grunwald; Patrick Ziegelmüller; Michael A. Kock Advances in Experimental Medicine and Biology 391 (Natural Toxins 2) 97-114 (1996) |
| 17 |
In vivo binding pair pretargeting using targeting moiety-affinity component conjugate and affinity component binding partner-functional moiety conjugate Nicholas Pomato; Richard P. McCabe; Gregory A. Hawkins; Reinhard Bredehorst; Chong-Ho Kim; Carl-Wilhelm Vogel Patent: US 5578289 (A) 1996-11-26 |
1995 | |
| 18 |
Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation Jane J. Zara; Nicholas Pomato; Richard P. McCabe; Reinhard Bredehorst; Carl-Wilhelm Vogel Bioconjugate Chemistry 6, 367-372 (1995) |
| 19 |
Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients Markus W. Ollert; Christine Wende; Martin Görlich; Candice G. McMullanvogel; Margarete Borg-Von Zepelin; Carl-Wilhelm Vogel; Hans Christian Korting Journal of Clinical Microbiology 33, 2543-2549 (1995) |
| 20 |
Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b Markus W. Ollert; Kerstin A. David; Reinhard Bredehorst; Carl-Wilhelm Vogel Journal of Immunology 155, 4955-4962 (1995) |
| 21 |
Molecular cloning and derived primary structure of cobra venom factor David C. Fritzinger; Reinhard Bredehorst; Carl-Wilhelm Vogel Proceedings of the National Academy of Sciences of the United States of America 92, 7605-7605 (1995) |
| 22 |
Immunoconjugates in medicine (in Chinese) Reinhard Bredehorst; Carl-Wilhelm Vogel -/- Herausgeber: Fuan Wang Internalization of Biological Macromolecules 223-236 (1995), Verlag: Science Press, Beijing |
| 23 |
Protease-derivatized cobra venom factor Markus W. Ollert; Patrick Ziegelmüller; Thomas Grunwald; Reinhard Bredehorst; Carl-Wilhelm Vogel Patent: WO 9507299 (A1) 1995-03-16 |
1994 | |
| 24 |
Immunoreactivity and function of oligosaccharides in cobra venom factor D. Channe Gowda; Eugene C. Petrella; T. Tilak Raj; Reinhard Bredehorst; Carl-Wilhelm Vogel Journal of Immunology 152, 2977-2986 (1994) |
| 25 |
Antibody-mediated complement activation on nucleated cells Markus W. Ollert; Joseph V. Kadlec; Kerstin A. David; Eugene C. Petrella; Reinhard Bredehorst; Carl-Wilhelm Vogel Journal of Immunology 153, 2213-2221 (1994) |
| 26 |
Molecular cloning and derived primary structure of cobra venom factor David C. Fritzinger; Reinhard Bredehorst; Carl-Wilhelm Vogel Proceedings of the National Academy of Sciences of the United States of America 91, 12775-12779 (1994) |
| 27 |
Cobra venom factor, the complement-activating protein of cobra venom: Molecular cloning and derived primary structure David C. Fritzinger; Michael A. Kock; Thomas Grunwald; Patrick Ziegelmüller; B. Kunze; Markus W. Ollert; Reinhard Bredehorst; Carl-Wilhelm Vogel -/- Herausgeber: R. Ansorge Schlaglichter der Forschung. Zum 75. Jahrestag der Universität Hamburg 565-591 (1994), Verlag: Dietrich Reiner Verlag, Berlin, Hamburg |
| 28 |
Molecular cloning of cDNA for cobra complement C3 and its analogs CVF1 and CVF2 David C. Fritzinger; Reinhard Bredehorst; Carl-Wilhelm Vogel Patent: WO 9423024 (A1) 1994-10-13 |
1993 | |
| 29 |
Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65 Markus W. Ollert; Joseph V. Kadlec; Eugene C. Petrella; Reinhard Bredehorst; Carl-Wilhelm Vogel Cancer Research 53, 592-599 (1993) |
| 30 |
Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system Gregory A. Hawkins; Richard P. McCabe; Chong-Ho Kim; Ramaswamy Subramanian; Reinhard Bredehorst; Gregory A. McCullers; Carl-Wilhelm Vogel; Michael G. Hanna; Nicholas Pomato Cancer Research 53, 2368-2373 (1993) |
| 31 |
In vivo binding pair pretargeting for site-specific delivery of functional moiety in radioimaging or radiotherapy Nicholas Pomato; Richard P. McCabe; Gregory A. Hawkins; Reinhard Brederhorst; Chong-Ho Kim; Carl-Wilhelm Vogel Patent: WO 9317707 (A1) 1993-09-16 |
1992 | |
| 32 |
Primary structure of cobra complement component C3 David C. Fritzinger; Eugene C. Petrella; Mark B. Connelly; Reinhard Bredehorst; Carl-Wilhelm Vogel Journal of Immunology 149, 3554-3562 (1992) |
| 33 |
Structure of the major oligosaccharide of cobra venom factor D. Channe Gowda; Michael Schultz; Reinhard Bredehorst; Carl-Wilhelm Vogel Molecular Immunology 29, 335-342 (1992) |
| 34 |
Continuous flow immunoassay: use of a novel trifunctional carrier molecule for the synthesis of fluorophore-labeled antigens Reinhard Bredehorst; Gregory A. Wemhoff; Anne W. Kusterbeck; Paul T. Charles; Frances S. Ligler; Carl-Wilhelm Vogel GBF Monographs 17 (Fundamentals, Technologies and Applications) 453-460 (1992) |
1991 | |
| 35 |
Novel trifunctional carrier molecule for the fluorescent labeling of haptens Reinhard Bredehorst; Gregory A. Wemhoff; Anne W. Kusterbeck; Paul T. Charles; Richard B. Thompson; Frances S. Ligler; Carl-Wilhelm Vogel Analytical Biochemistry 193, 272-279 (1991) |
| 36 |
A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates Jane J. Zara; Richard D. Wood; Peter Boon; Chong-Ho Kim; Nicholas Pomato; Reinhard Bredehorst; Carl-Wilhelm Vogel Analytical Biochemistry 194, 156-162 (1991) |
| 37 |
Ligand-label conjugates which contain polyoxoanions of sulfur or phosphorus Reinhard Bredehorst; Frances S. Ligler; Anne W. Kusterbeck; Gregory A. Wemhoff; Carl-Wilhelm Vogel Patent: WO 9116344 (A1) 1991-10-31 |
1990 | |
| 38 |
A continuous flow immunoassay for rapid and sensitive detection of small molecules Anne W. Kusterbeck; Gregory A. Wemhoff; Paul T. Charles; Doyle A. Yeager; Reinhard Bredehorst; Carl-Wilhelm Vogel; Frances S. Ligler Journal of Immunological Methods 135, 191-197 (1990) |
| 39 |
C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells Markus W. Ollert; Raymond Frade; Anny Fiandino; Mounanandham Panneerselvam; Eugene C. Petrella; Monique Barel; Michael K. Pangburn; Reinhard Bredehorst; Carl-Wilhelm Vogel Journal of Immunology 144, 3862-3867 (1990) |
| 40 |
Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab)'2-cobra venom factor conjugate are equally cytotoxic Hartmut Juhl; Eugene C. Petrella; Nai-Kong V. Cheung; Reinhard Bredehorst; Carl-Wilhelm Vogel Molecular Immunology 27, 957-964 (1990) |
| 41 |
Specific elimination of human Neuroblastoma cells by monoclonal antibody-cobra venom factor conjugates: a tumor therapy model Hartmut Juhl; Eugene C. Petrella; Nai-Kong V. Cheung; Reinhard Bredehorst; Carl-Wilhelm Vogel -/- Herausgeber: R. Häring; K. Messmer; E. Ungeheuer Chirurgisches Forum '90 für experimentelle und klinische Forschung 289-295 (1990), Verlag: Springer-Verlag, Berlin, Heidelberg |
| 42 |
The central role of cell surface-deposited C3b for the Complement susceptibility of human melanoma cells Reinhard Bredehorst; Carl-Wilhelm Vogel -/- Herausgeber: S. Ferrone Human Melanoma. Immunology, Diagnostics and Therapy 133-150 (1990), Verlag: Springer Verlag, Berlin, Heidelberg |
| 43 |
Site-specific in-vivo activation of prodrugs Reinhard Bredehorst; Chong-Ho Kim; Richard McCabe; Nicholas Pomato; Carl-Wilhelm Vogel Patent: WO 9007929 (A1) 1990-07-26 |
| 44 |
Preparation of site-specific heterobifunctional crosslinking reagents, their use, and kits containing them Jane J. Zara; Richard D. Wood; Reinhard Bredehorst; Carl-Wilhelm Vogel Patent: WO 9010621 (A1) 1990-09-20 |
1989 | |
| 45 |
The oligosaccharide chains of cobra venom factor are required for complement activation Alice H. Grier; Carl-Wilhelm Vogel Molecular Immunology 26, 563-574 (1989) |
1988 | |
| 46 |
Differences in uptake of mycobacteria by human monocytes: a role for complement Rodney P. Swartz; David Naai; Carl-Wilhelm Vogel; Henry Yeager Infection and Immunity 56, 2223-2227 (1988) |
| 47 |
A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor M. Clare O'Keefe; Lynn H. Caporale; Carl-Wilhelm Vogel Journal of Biological Chemistry 263, 12690-12697 (1988) |
| 48 |
Synthesis of antibody conjugates with cobra venom factor using heterobifunctional cross-linking reagents Carl-Wilhelm Vogel Targeted Diagnosis and Therapy 1, 191-224 (1988) |
| 49 |
Potential use of monoclonal antibody-drug conjugates to prevent drug resistance Carl-Wilhelm Vogel; Reinhard Bredehorst; Mounanandham Panneerselvam; Carole J. Spangler -/- Herausgeber: P. V. Woolley; K. P. Tew Bristol-Myers Cancer Symposia 9 (Mechanisms of Drug Resistance in Neoplastic Cells) 371-383 (1988), Verlag: Academic Press, New York |
| 50 |
Detectably labeled cephalosporin assay for β-lactamase determination Reinhard Bredehorst; Abdolhossen Talebian; Charles F. Hammer; Carl-Wilhelm Vogel Patent: US 4764462 (A) 1988-08-16 |
1987 | |
| 51 |
A homogeneous immunoassay for the mycotoxin T-2 utilizing liposomes, monoclonal antibodies, and complement Frances S. Ligler; Reinhard Bredehorst; Abdolhossen Talebian; Lisa C. Shriver; Charles F. Hammer; James P. Sheridan; Carl-Wilhelm Vogel; Bruce P. Gaber Analytical Biochemistry 163, 369-375 (1987) |
| 52 |
Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin Mounanandham Panneerselvam; Reinhard Bredehorst; Carl-Wilhelm Vogel Cancer Research 47, 4601-4607 (1987) |
| 53 |
Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells Sydney Welt; Elizabeth A. Carswell; Carl-Wilhelm Vogel; Herbert F. Oettgen; Lloyd J. Old Clinical Immunology and Immunopathology 45, 214-229 (1987) |
| 54 |
Doxorubicin enhances complement susceptibility of human melanoma cells by extracellular oxygen radical formation Reinhard Bredehorst; Mounanandham Panneerselvam; Carl-Wilhelm Vogel Journal of Biological Chemistry 262, 2034-2041 (1987) |
| 55 |
Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization Eugene C. Petrella; Scott D. Wilkie; Craig A. Smith; Alton C. Morgan; Carl-Wilhelm Vogel Journal of Immunological Methods 104, 159-172 (1987) |
| 56 |
Cobra venom factor and human C3 share carbohydrate antigenic determinants Alice H. Grier; Michael Schultz; Carl-Wilhelm Vogel Journal of Immunology 139, 1245-1252 (1987) |
| 57 |
Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer Herausgeber: Carl-Wilhelm Vogel Verlag: Oxford Univ. Press, New York (1987) |
1986 | |
| 58 |
Effects of a complex combining an alternative-pathway complement activator with a nonactivating anti-Entamoeba histolytica monoclonal antibody Carl-Wilhelm Vogel; Ricardo Alaniz; Ruth Capin; Librado Ortiz-Ortiz Archivos de Investigacion Medica 17, 269-271 (1986) |
| 59 |
Effect of covalent attachment of immunoglobulin fragments on liposomal integrity Reinhard Bredehorst; Frances S. Ligler; Anne W. Kusterbeck; Eddie L. Chang; Bruce P. Gaber; Carl-Wilhelm Vogel Biochemistry 25, 5693-5698 (1986) |
| 60 |
The effect of complement depletion on immunologically mediated middle ear effusion and inflammation A. F. Ryan; A. Catanzaro; S. I. Wasserman; J. P. Harris; Carl-Wilhelm Vogel Clinical Immunology and Immunopathology 40, 410-421 (1986) |
| 61 |
The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B Preston Hensley; M. Clare O'Keefe; Carole J. Spangler; James C. Osborne; Carl-Wilhelm Vogel Journal of Biological Chemistry 261, 11038-11044 (1986) |
| 62 |
A molecular mechanism of complement resistance of human melanoma cells Mounanandham Panneerselvam; Sydney Welt; Lloyd J. Old; Carl-Wilhelm Vogel Journal of Immunology 136, 2534-2541 (1986) |
| 63 |
Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation Mounanandham Panneerselvam; Reinhard Bredehorst; Carl-Wilhelm Vogel Proceedings of the National Academy of Sciences of the United States of America 83, 9144-9148 (1986) |
1985 | |
| 64 |
The cobra complement system: I. The alternative pathway of activation Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Developmental & Comparative Immunology 9, 311-325 (1985) |
| 65 |
The cobra complement system: II. The membrane attack complex Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Developmental & Comparative Immunology 9, 327-333 (1985) |
| 66 |
Untersuchungen zur Strukturhomologie von Kobrafaktor mit dem menschlichen Komplementprotein C3 sowie Synthese kovalenter Hybridproteine aus Kobrafaktor und monoklonalen Antikörpern als selektiv-zytotoxisches Prinzip Carl-Wilhelm Vogel -/- Betreuer: Günther Gercken Dissertation, Hamburg (1985) |
| 67 |
In vivo studies with covalent conjugates of cobra venom factor and monoclonal antibodies to human tumors Carl-Wilhelm Vogel; Scott D. Wilkie; Alton C. Morgan -/- Herausgeber: Rolf Neth Haematology and Blood Transfusion 29 (Modern trends in human leukemia VI : new results in clinical and biological research including pediatric oncology ; Wilsede Joint Meeting on Pediatric Oncology 3, Hamburg , June 21/22, 1984 ) 514-517 (1985) |
1984 | |
| 68 |
Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement Craig A. Smith; Michael K. Pangburn; Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Journal of Biological Chemistry 259, 4582-4588 (1984) |
| 69 |
MHC class III products: an electron microscopic study of the C3 convertases of human complement Craig A. Smith; Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Journal of Experimental Medicine 159, 324-329 (1984) |
| 70 |
Cobra venom factor: improved method for purification and biochemical characterization Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Journal of Immunological Methods 73, 203-220 (1984) |
| 71 |
Cobra venom factor: structural homology with the third component of human complement Carl-Wilhelm Vogel; Craig A. Smith; Hans J. Müller-Eberhard Journal of Immunology 133, 3235-3241 (1984) |
1983 | |
| 72 |
The membrane attack complex of complement and its precursor proteins lack phospholipase activity Carl-Wilhelm Vogel; Andreas Plückthun; Eckhard R. Podack; Edward A. Dennis; Hans J. Müller-Eberhard Molecular Immunology 20, 377-382 (1983) |
1982 | |
| 73 |
The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Journal of Biological Chemistry 257, 8292-8299 (1982) |
| 74 |
Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement Craig A. Smith; Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Journal of Biological Chemistry 257, 9879-9882 (1982) |
1981 | |
| 75 |
Hemolytic assay for venom phospholipase A2 Carl-Wilhelm Vogel; Andreas Plückthun; Hans J. Müller-Eberhard; Edward A. Dennis Analytical Biochemistry 118, 262-268 (1981) |
| 76 |
Induction of immune cytolysis: Tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase Carl-Wilhelm Vogel; Hans J. Müller-Eberhard Proceedings of the National Academy of Sciences of the United States of America 78, 7707-7711 (1981) |
1979 | |
| 77 |
A new cAMP affinity matrix for the rapid purification of protein kinase regulatory subunits Wolfgang Weber; Carl-Wilhelm Vogel; Helmuth Hilz FEBS Letters 99, 62-66 (1979) |
1976 | |
| 78 |
Verbesserung der fluoreszenzspektralphotometrischen Methode und Entwicklung einer spektraldensitometrischen Methode zur Bestimmung von Chloroquin in biologischen Flüssigkeiten Carl-Wilhelm Vogel -/- Betreuer: Eberhard Königk Dissertation (med), Hamburg (1976) |
1975 | |
| 79 |
Spectrofluorometric and spectrodensitometric determination of chloroquine in plasma and urine Carl-Wilhelm Vogel; Eberhard Königk Tropenmedizin und Parasitologie 26, 278-280 (1975) |
